Zealand Pharma Initiation: Shifting pounds into profit
Zealand is a Danish biotech with a broad pipeline in obesity and rare disease. Petrelintide (amylin analog) could become a monotherapy challenger to GLP-1 drugs based on its efficacy and tolerability in phase 1b, and phase 2b results in 2026 could set petrelintide up to capture a significant share of the $140b obesity market as the go to option for GLP-1 intolerant patients, weight loss maintenance and beyond. In addition, survodutide (GLP-1/glucagon analog) is already out-licenced to BI with ongoing phase 3 trials in obesity with and without T2D, and has shown a strong anti-fibrotic effect in MASH. With a differentiated obesity pipeline and 2 rare disease products nearing FDA approval, we see significant upside to the current valuation and initiate coverage with a DKK 980 TP and BUY rating.Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.